EURIPID Survey Shines Spotlight on Drug Price Transparency and Confidential Payer-Pharma Agreements

A recent article, published in Health Policy, highlights the use of confidential managed-entry agreements (MEAs) between payers and pharma throughout Europe. The use of confidential agreements is legally binding in some countries, making the true cost of prescription drugs difficult to determine.

“The EURIPID Executive Committee surveyed 22 European countries, who all reported the use of confidential agreements between pharmaceutical companies and public payers, confirming that the actual prices paid are typically lower than the published list price.” Read more here.

(Source: Russo et al., Health Policy, 9/21)